Since the 2017 landmark FDA and EMA approvals of the first ever chimeric antigen receptor T (CAR-T) therapies, Kymriah and Yescarta, the cancer cell therapy field has exploded in growth. In fact, hundreds of new investigational cell therapies have been added each year, nearly quadrupling since 2017. The 1,597 cell therapies in active development now represent the largest therapeutic platform category in the immune-oncology space.
All of the cancer cell therapies on the market, and a majority of clinical assets (about 75 percent) are autologousii, meaning the cell therapy treats the same individual from whom these cells are derived.
